Idecabtagene vicleucel for R/R multiple myeloma with renal impairment

Ide-cel therapy for multiple myeloma with renal impairmentПодробнее

Idecabtagene Vicleucel in Pts with Relapsed and Refractory Multiple Myeloma: Updated KarMMa ResultsПодробнее

$Idecabtagene Vicleucel in Pts with Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results$

DARE: dara for R/R myeloma with renal impairmentПодробнее

Pomalidomide with dexamethasone in relapsed/refractory multiple myeloma with renal impairmentПодробнее

$Pomalidomide with dexamethasone in relapsed/refractory multiple myeloma with renal impairment$

Idecabtagene vicleucel for R/R myelomaПодробнее

Causes & management of renal impairment in patients with multiple myelomaПодробнее

Managing and treating renal impairment in multiple myelomaПодробнее

Dr. Morgan on Idecabtagene Vicleucel in Multiple MyelomaПодробнее

Dr. Voorhees on the Effectiveness of Idecabtagene Vicleucel in Multiple MyelomaПодробнее

The impact of renal impairment on the MM treatment strategyПодробнее

Improving the inclusion of patients with multiple myeloma with renal impairment in clinical trialsПодробнее

KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in HRMM Pts with Early Relapse after ASCTПодробнее

Dara plus dex in R/R myeloma patients with renal impairmentПодробнее

Efficacy of anti-myeloma therapies following relapse on idecabtagene vicleucelПодробнее

KarMMa: Idecabtagene vicleucel for R/R MMПодробнее

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa resultsПодробнее

GMMG-DANTE: DVd in patients with multiple myeloma and renal impairmentПодробнее

Idecabtagene vicleucel for relapsed and refractory multiple myelomaПодробнее

$Idecabtagene vicleucel for relapsed and refractory multiple myeloma$

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) f... | RTCL.TVПодробнее